[go: up one dir, main page]

MX2024013959A - Proteinas de fusion del hmpv estabilizadas por prefusion - Google Patents

Proteinas de fusion del hmpv estabilizadas por prefusion

Info

Publication number
MX2024013959A
MX2024013959A MX2024013959A MX2024013959A MX2024013959A MX 2024013959 A MX2024013959 A MX 2024013959A MX 2024013959 A MX2024013959 A MX 2024013959A MX 2024013959 A MX2024013959 A MX 2024013959A MX 2024013959 A MX2024013959 A MX 2024013959A
Authority
MX
Mexico
Prior art keywords
fusion
hmpv
proteins
stabilized pre
fusion proteins
Prior art date
Application number
MX2024013959A
Other languages
English (en)
Inventor
Johannes Petrus Maria Langedijk
Mark Johannes Gerardus Bakkers
Tina Ritschel
Jaroslaw Juraszek
Original Assignee
Msd Int Business Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msd Int Business Gmbh filed Critical Msd Int Business Gmbh
Publication of MX2024013959A publication Critical patent/MX2024013959A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a proteínas F de neumovirus humano estabilizadas por prefusión (HMPV), a moléculas de ácido nucleico que codifican dichas proteínas F del HMPV, así como también al uso de las mismas.
MX2024013959A 2022-05-12 2024-11-11 Proteinas de fusion del hmpv estabilizadas por prefusion MX2024013959A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22173131 2022-05-12
PCT/EP2023/062652 WO2023217988A1 (en) 2022-05-12 2023-05-11 Stabilized pre-fusion hmpv fusion proteins

Publications (1)

Publication Number Publication Date
MX2024013959A true MX2024013959A (es) 2025-02-10

Family

ID=81653543

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024013959A MX2024013959A (es) 2022-05-12 2024-11-11 Proteinas de fusion del hmpv estabilizadas por prefusion

Country Status (15)

Country Link
EP (1) EP4522209A1 (es)
JP (1) JP2025521082A (es)
KR (1) KR20250010642A (es)
CN (1) CN119562826A (es)
AU (1) AU2023269241A1 (es)
CA (1) CA3253332A1 (es)
CL (1) CL2024003418A1 (es)
CO (1) CO2024015386A2 (es)
CR (1) CR20240493A (es)
DO (1) DOP2024000230A (es)
GE (1) GEAP202516650A (es)
IL (1) IL316911A (es)
MX (1) MX2024013959A (es)
PE (1) PE20251395A1 (es)
WO (1) WO2023217988A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20252308A1 (es) 2023-01-18 2025-09-22 Pfizer Vacunas contra enfermedades respiratorias
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2025144636A1 (en) * 2023-12-26 2025-07-03 The Scripps Research Institute ENGINEERED hMPV F PROTEIN IMMUNOGENS AND RELATED VACCINES
WO2025163460A2 (en) * 2024-01-30 2025-08-07 Pfizer Inc. Vaccines against respiratory diseases
US20260021175A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
CN100497639C (zh) 2002-04-25 2009-06-10 克鲁塞尔荷兰公司 生产腺病毒载体的手段和方法
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
CN110073002B (zh) 2016-10-17 2024-06-11 杨森制药公司 重组病毒复制子体系及其用途
MX2019006467A (es) 2016-12-05 2019-12-09 Janssen Pharmaceuticals Inc Star Composiciones y métodos para mejorar la expresión génica.
US20230085439A1 (en) * 2019-05-21 2023-03-16 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use
IL301950B2 (en) * 2020-10-09 2025-09-01 Univ Texas Pre-stabilized hmpv f proteins

Also Published As

Publication number Publication date
WO2023217988A1 (en) 2023-11-16
CR20240493A (es) 2025-01-29
CO2024015386A2 (es) 2024-11-28
IL316911A (en) 2025-01-01
DOP2024000230A (es) 2025-02-16
CL2024003418A1 (es) 2025-08-01
CA3253332A1 (en) 2023-11-16
GEAP202516650A (en) 2025-03-10
KR20250010642A (ko) 2025-01-21
PE20251395A1 (es) 2025-05-22
CN119562826A (zh) 2025-03-04
AU2023269241A1 (en) 2024-11-21
EP4522209A1 (en) 2025-03-19
JP2025521082A (ja) 2025-07-08

Similar Documents

Publication Publication Date Title
MX2024013959A (es) Proteinas de fusion del hmpv estabilizadas por prefusion
BR112018072946A2 (pt) proteínas de fusão a gdf15 e usos das mesmas
MX2020007945A (es) Proteinas f del rsv estabilizadas y usos de las mismas.
MX2018016114A (es) Una novedosa fructosa-6-fosfato-3-epimerasa termoestable y un procedimiento para producir alulosa mediante el uso de la misma.
BR112015017307A2 (pt) composições de espécies com baixa acidez e métodos para produção e uso das mesmas
CR20200327A (es) Proteínas de fusión fc il-22 y métodos de uso
MY167231A (en) Amino acid sequences directed against IL-17A, IL-17F and/or IL17-A/F and polypeptides comprising the same
CY1110860T1 (el) Αναστροφη μεταγραφαση τελομερασης πτηνου
MX2024014468A (es) Anticuerpos anti-cd63, conjugados y usos de estos
CR20110639A (es) Mutantes fgf21 y usos de los mismos
MX2010005783A (es) Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
MX2012000036A (es) Vacuna.
TW200716674A (en) Anti-GM-CSF antibodies and uses therefor
CR11851A (es) Mutantes fgf21 y usos de los mismos
MX2009002816A (es) Proteinas de fusion de albumina.
TNSN08064A1 (en) Albumin fusion proteins
SG10201906859PA (en) Novel proteins specific for angiogenesis
MX2023011629A (es) Proteinas piv3 f prefusion estabilizadas.
MX394221B (es) Metodos de reduccion de olor.
MX360085B (es) Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso.
PH12021551422A1 (en) Anti-il-36 antibodies and methods of use thereof
EP2496608A4 (en) FUSION PROTEIN FOR THE SPECIFIC BINDING OF CONSTANT ANTIBODY REGIONS, PREPARATION THEREOF, AND METHOD FOR THE ANTIBODY INSULATION THEREWITH
SV2017005545A (es) Fusiones de variante iii del receptor de factor de crecimiento epidermico-mesotelina y metodos para usar los mismos
GB2534315A (en) WNT compositions and methods for purification
GB2469395A (en) Methods and compounds for phototransfer